trending Market Intelligence /marketintelligence/en/news-insights/trending/nlakl688kacy5qfzfwmqdg2 content esgSubNav
In This List

MabVax Therapeutics closes $2.1M private placement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


MabVax Therapeutics closes $2.1M private placement

MabVax Therapeutics Holdings Inc. raised $2.1 million via the sale of company shares to accredited investors.

The shares were sold at 75 cents each and came bundled with 0.7 of a purchase warrant. Each whole warrant can be exercised into a share of a company for 90 cents apiece.

The San Diego-based biotechnology company will use proceeds to continue development of its potential cancer treatments MVT-5873 and MVT-1075.

The MabVax board also approved a 1-for-3 reverse stock split to help the company regain compliance with Nasdaq's $1 minimum closing bid price requirement.

MabVax's stockholders approved the reverse stock split in October 2017.